VIENNA, October 5th:
The World Congress of Lung Cancer is the world’s largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology (https://wclc2022.iaslc.org). We could not have chosen a better stage to introduce BiomeOne®for the first time.
This work provides an insight into the development of the intestinal microbiome signature that allows our test to predict the response to cancer immunotherapy (immune checkpoint inhibitors) and shows our model validation results in a NSCLC cohort.
About BiomeOne®
BiomeOne® describes the current efforts of BiomeDx® towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker, that can be used for any tumor type. Read more on BiomeOne®.
About BiomeDx®
Biome Diagnostics GmbH (BiomeDx®) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
Presented poster: Introducing “BiomeOne”, a microbiome-based biomarker to predict immune checkpoint inhibitor response in NSCLC patients